Summit Hotel Properties, Inc. (INN-PE)

Compare

20.05

+0.10

+(0.50%)

At close: March 11 at 3:59:41 PM EDT

Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it has closed its previously announced non-brokered private placement offering of a debenture unit of the Company (the "Debenture Unit") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $1,000,000 (the "Offering").

CNW Group 4 days ago

INN

INN-PE
+0.50%
INN-PF
Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete an offering of a debenture unit of the Company (the "Debenture Unit") to its largest shareholder, Tamar Innovest Ltd. ("Tamar Innovest") for gross proceeds of US $1,000,000 (the "Offering").

CNW Group 12 days ago

INN

INN-PE
+0.50%
INN-PF
INN vs. GLPI: Which Stock Is the Better Value Option?

INN vs. GLPI: Which Stock Is the Better Value Option?

Zacks 13 days ago

INN

GLPI
Should Value Investors Buy Summit Hotel Properties (INN) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks 13 days ago

INN
Summit Hotel Properties Inc (INN) Q4 2024 Earnings Call Highlights: Strong AFFO Growth and ...

Summit Hotel Properties Inc (INN) reports nearly 6% AFFO per share growth and strategic acquisitions, despite challenging market conditions.

GuruFocus.com 14 days ago

INN
Q4 2024 Summit Hotel Properties Inc Earnings Call

Q4 2024 Summit Hotel Properties Inc Earnings Call

Thomson Reuters StreetEvents 14 days ago

INN
Summit Hotel Properties (INN) Q4 FFO and Revenues Beat Estimates

Summit Hotel Properties (INN) delivered FFO and revenue surprises of 5.26% and 1.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 15 days ago

INN

ALEX
Summit Hotel Properties: Q4 Earnings Snapshot

The results topped Wall Street expectations. The Austin, Texas-based real estate investment trust said it had funds from operations of $25.2 million, or 20 cents per share, in the period. The average estimate of three analysts surveyed by Zacks Investment Research was for funds from operations of 19 cents per share.

Associated Press Finance 15 days ago

INN
SUMMIT HOTEL PROPERTIES REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the three and twelve months ended December 31, 2024.

PR Newswire 15 days ago

INN

INN-PE
+0.50%
INN-PF
Summit Hotel Properties Announces 2025 Annual Meeting of Stockholders

Summit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that its 2025 Annual Meeting of Stockholders will be held Wednesday, May 21, 2025, beginning at 8:00 a.m. Eastern Time. The meeting will be held at the Courtyard by Marriott Oceanside Fort Lauderdale Beach located at 440 Seabreeze Boulevard, Fort Lauderdale, Florida 33316. The meeting is open to all stockholders of record as of March 5, 2025.

PR Newswire 19 days ago

INN

INN-PE
+0.50%
INN-PF
Park Hotels & Resorts (PK) Q4 FFO Miss Estimates

Park Hotels & Resorts (PK) delivered FFO and revenue surprises of -2.50% and 3.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 20 days ago

PK

INN
Summit Hotel Properties (INN): Among the Best Hotel Stocks to Buy According to Analysts

We recently published a list of the 12 Best Hotel Stocks To Buy According to Analysts. In this article, we are going to take a look at where Summit Hotel Properties, Inc. (NYSE:INN) stands against other best hotel stocks to buy according to analysts. Overview of the Hospitality Industry The hospitality industry is undergoing a […]

Insider Monkey 23 days ago

INN
Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful outcome from the compassionate treatment of a female donkey with its innovative liposomal CBD injection (LPT-CBD). Innocan's innovative therapy provided quick and sustained pain relief, significantly improving mobility in an elderly female donkey suffering from osteoarthritis.

CNW Group 29 days ago

INNPF

INN

INN-PE
+0.50%
Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that its subsidiary, BI Sky Global (BI), successfully completed the Human Repeated Insult Patch Test (HRIPT) for Sensitization and Irritation Testing, ensuring the safety of its cosmetic products. HRIPT is the personal care industry's standard safety test for cosmetic, OTC drug, and topical medical devices.

CNW Group last month

INN

INN-PE
+0.50%
INN-PF
SUMMIT HOTEL PROPERTIES DECLARES FOURTH QUARTER 2024 DIVIDENDS

Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), announced today that its Board of Directors has authorized, and the Company has declared, a cash dividend for the fourth quarter ended December 31, 2024, of $0.08 per share of common stock of the Company and per common unit of limited partnership interest in Summit Hotel OP, LP, the Company's operating partnership. The Company's fourth quarter common dividend represents an annualized dividend yield of 4.8 percent based on the closing pri

PR Newswire last month

INN

INN-PE
+0.50%
INN-PF
SUMMIT HOTEL PROPERTIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RELEASE DATE

Summit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that it will report financial results for the fourth quarter and full year of 2024 on Monday, February 24, 2025, after the market closes.

PR Newswire last month

INN

INN-PE
+0.50%
INN-PF
FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the second consecutive year.

CNW Group last month

INN

INN-PE
+0.50%
INN-PF
Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 3,177,223 Units at a price of C$0.20 per Unit (the "Offering Price") for aggregate gross proceeds of $635,444.60.

CNW Group 2 months ago

INN

INN-PE
+0.50%
INN-PF
Innocan Pharma Announces Private Placement of Units

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that it intends to complete a non-brokered private placement of up to [3,500,000] units of the Company (the "Units") at a price of [C$0.20] per Unit for gross proceeds up to C$700,000 plus 15% over allotment options (the "Offering"). The Offering is expected to close on or around December 31, 2024.

CNW Group 2 months ago

INNPF

INN

INN-PE
+0.50%
Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual "State of Research and Development" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual

CNW Group 2 months ago

INNPF

INN

INN-PE
+0.50%

Performance Overview

Return	INN-PE	S&P 500
YTD	-0.09%	-5.26%
1-Year	+3.41%	+8.87%
3-Year	+4.58%	+32.53%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Summit Hotel Properties, Inc. (INN-PE)

Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited

Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest

INN vs. GLPI: Which Stock Is the Better Value Option?

Should Value Investors Buy Summit Hotel Properties (INN) Stock?

Summit Hotel Properties Inc (INN) Q4 2024 Earnings Call Highlights: Strong AFFO Growth and ...

Q4 2024 Summit Hotel Properties Inc Earnings Call

Summit Hotel Properties (INN) Q4 FFO and Revenues Beat Estimates

Summit Hotel Properties: Q4 Earnings Snapshot

SUMMIT HOTEL PROPERTIES REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Summit Hotel Properties Announces 2025 Annual Meeting of Stockholders

Park Hotels & Resorts (PK) Q4 FFO Miss Estimates

Summit Hotel Properties (INN): Among the Best Hotel Stocks to Buy According to Analysts

Innocan Pharma's Liposomal CBD Injection Shows Breakthrough Pain Relief in Elderly Donkey with Osteoarthritis

Innocan Pharma's Subsidiary BI Sky Global Completes HRIPT Testing and Surpasses Important Sales Milestone

SUMMIT HOTEL PROPERTIES DECLARES FOURTH QUARTER 2024 DIVIDENDS

SUMMIT HOTEL PROPERTIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RELEASE DATE

FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025

Innocan Pharma Announces Closing of Private Placement for Gross Proceeds of C$635,444.60

Innocan Pharma Announces Private Placement of Units

Innocan Pharma Provides its Annual "State of Research and Development" Update for 2024

Performance Overview